IL
Illinois House Bill HB2309

Illinois 2023-2024 Regular Session

Illinois House Bill HB2309 Compare Versions

Only one version of the bill is available at this time.
OldNewDifferences
11 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB2309 Introduced , by Rep. Lindsey LaPointe SYNOPSIS AS INTRODUCED: 305 ILCS 65/15 new Amends the Early Mental Health and Addictions Treatment Act. Requires the Department of Human Services to implement a 2-year pilot program to provide FDA-approved 8-milligram naloxone nasal spray kits to licensed community substance use providers and public health departments in Cook County, DuPage County, Winnebago County, Sangamon County, and St. Clair County. Requires the Department to implement a data collection program to determine the number of 8-milligram naloxone nasal spray kits administered by emergency medical service providers and bystanders per overdose incident during the 2-year term of the pilot program. Provides that the data collected must also include the number of overdose reversals and deaths following the administration of the 8-milligram naloxone nasal spray. Requires the Department to prepare a report on the results of the 2-year pilot program and submit the report to the General Assembly by July 1, 2026. Effective January 1, 2024. LRB103 25361 KTG 51706 b A BILL FOR 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB2309 Introduced , by Rep. Lindsey LaPointe SYNOPSIS AS INTRODUCED: 305 ILCS 65/15 new 305 ILCS 65/15 new Amends the Early Mental Health and Addictions Treatment Act. Requires the Department of Human Services to implement a 2-year pilot program to provide FDA-approved 8-milligram naloxone nasal spray kits to licensed community substance use providers and public health departments in Cook County, DuPage County, Winnebago County, Sangamon County, and St. Clair County. Requires the Department to implement a data collection program to determine the number of 8-milligram naloxone nasal spray kits administered by emergency medical service providers and bystanders per overdose incident during the 2-year term of the pilot program. Provides that the data collected must also include the number of overdose reversals and deaths following the administration of the 8-milligram naloxone nasal spray. Requires the Department to prepare a report on the results of the 2-year pilot program and submit the report to the General Assembly by July 1, 2026. Effective January 1, 2024. LRB103 25361 KTG 51706 b LRB103 25361 KTG 51706 b A BILL FOR
22 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB2309 Introduced , by Rep. Lindsey LaPointe SYNOPSIS AS INTRODUCED:
33 305 ILCS 65/15 new 305 ILCS 65/15 new
44 305 ILCS 65/15 new
55 Amends the Early Mental Health and Addictions Treatment Act. Requires the Department of Human Services to implement a 2-year pilot program to provide FDA-approved 8-milligram naloxone nasal spray kits to licensed community substance use providers and public health departments in Cook County, DuPage County, Winnebago County, Sangamon County, and St. Clair County. Requires the Department to implement a data collection program to determine the number of 8-milligram naloxone nasal spray kits administered by emergency medical service providers and bystanders per overdose incident during the 2-year term of the pilot program. Provides that the data collected must also include the number of overdose reversals and deaths following the administration of the 8-milligram naloxone nasal spray. Requires the Department to prepare a report on the results of the 2-year pilot program and submit the report to the General Assembly by July 1, 2026. Effective January 1, 2024.
66 LRB103 25361 KTG 51706 b LRB103 25361 KTG 51706 b
77 LRB103 25361 KTG 51706 b
88 A BILL FOR
99 HB2309LRB103 25361 KTG 51706 b HB2309 LRB103 25361 KTG 51706 b
1010 HB2309 LRB103 25361 KTG 51706 b
1111 1 AN ACT concerning public aid.
1212 2 Be it enacted by the People of the State of Illinois,
1313 3 represented in the General Assembly:
1414 4 Section 5. The Early Mental Health and Addictions
1515 5 Treatment Act is amended by adding Section 15 as follows:
1616 6 (305 ILCS 65/15 new)
1717 7 Sec. 15. Pilot program for 8-milligram naloxone nasal
1818 8 spray kits.
1919 9 (a) Findings. The General Assembly finds the following:
2020 10 (1) In its May 2022 Statewide Semiannual Opioid
2121 11 Report, the Department of Public Health reported that
2222 12 3,013 fatalities occurred in 2021 due to opioid overdoses.
2323 13 (2) These 3,013 opioid overdose deaths in Illinois
2424 14 represent a 2.3% increase from 2020 and a 35.8% spike from
2525 15 2019.
2626 16 (3) In 2021, toxicology testing found that 2,672 or
2727 17 89% of the opioid fatalities involved a synthetic opioid
2828 18 such as fentanyl.
2929 19 (4) A 4-milligram naloxone nasal spray has been the
3030 20 principal tool for bystanders and emergency medical
3131 21 service providers to revive an individual from an overdose
3232 22 episode.
3333 23 (5) A study published in the Harm Reduction Journal in
3434
3535
3636
3737 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB2309 Introduced , by Rep. Lindsey LaPointe SYNOPSIS AS INTRODUCED:
3838 305 ILCS 65/15 new 305 ILCS 65/15 new
3939 305 ILCS 65/15 new
4040 Amends the Early Mental Health and Addictions Treatment Act. Requires the Department of Human Services to implement a 2-year pilot program to provide FDA-approved 8-milligram naloxone nasal spray kits to licensed community substance use providers and public health departments in Cook County, DuPage County, Winnebago County, Sangamon County, and St. Clair County. Requires the Department to implement a data collection program to determine the number of 8-milligram naloxone nasal spray kits administered by emergency medical service providers and bystanders per overdose incident during the 2-year term of the pilot program. Provides that the data collected must also include the number of overdose reversals and deaths following the administration of the 8-milligram naloxone nasal spray. Requires the Department to prepare a report on the results of the 2-year pilot program and submit the report to the General Assembly by July 1, 2026. Effective January 1, 2024.
4141 LRB103 25361 KTG 51706 b LRB103 25361 KTG 51706 b
4242 LRB103 25361 KTG 51706 b
4343 A BILL FOR
4444
4545
4646
4747
4848
4949 305 ILCS 65/15 new
5050
5151
5252
5353 LRB103 25361 KTG 51706 b
5454
5555
5656
5757
5858
5959
6060
6161
6262
6363 HB2309 LRB103 25361 KTG 51706 b
6464
6565
6666 HB2309- 2 -LRB103 25361 KTG 51706 b HB2309 - 2 - LRB103 25361 KTG 51706 b
6767 HB2309 - 2 - LRB103 25361 KTG 51706 b
6868 1 May 2022 surveyed 125 adult residents of the United States
6969 2 who were administered a 4-milligram naloxone nasal spray
7070 3 during an opioid overdose. The study found that 78% of the
7171 4 adults surveyed reported using at least 2 or more doses of
7272 5 the 4-milligram naloxone nasal spray. While 30% of the
7373 6 adults surveyed reported using at least 3 or more doses of
7474 7 the 4-milligram naloxone nasal spray.
7575 8 (6) A 2021 article published in the Harm Reduction
7676 9 Journal reported on a study conducted by the Johns Hopkins
7777 10 Bloomberg School of Public Health which surveyed 171
7878 11 people living in suburban Maryland who use opioids.
7979 12 Sixty-one or 35.7% of the persons surveyed reported having
8080 13 received take-home naloxone during the 6-month period
8181 14 immediately prior to the start of the study. 57% of those
8282 15 persons reported using it to reverse an overdose. Out of
8383 16 that group of persons who had an overdose reversal, 79%
8484 17 reported needing at least 2 or more doses of the take-home
8585 18 naloxone.
8686 19 (7) The National Library of Medicine recently
8787 20 published a study that analyzed emergency medical services
8888 21 (EMS) data collected and stored in the National Emergency
8989 22 Medical Services Information System database. The study
9090 23 examined data collected from over 10,000 EMS agencies
9191 24 across 47 states concerning 946,000 EMS calls that
9292 25 involved the administration of naloxone. The study found
9393 26 that naloxone multi-dosing by emergency medical service
9494
9595
9696
9797
9898
9999 HB2309 - 2 - LRB103 25361 KTG 51706 b
100100
101101
102102 HB2309- 3 -LRB103 25361 KTG 51706 b HB2309 - 3 - LRB103 25361 KTG 51706 b
103103 HB2309 - 3 - LRB103 25361 KTG 51706 b
104104 1 providers increased 54% over 5 years, from 18.4% to 28.4%
105105 2 in 2020.
106106 3 (8) On April 30, 2021, the U.S. Food and Drug
107107 4 Administration approved a higher 8-milligram dose naloxone
108108 5 nasal spray product to treat opioid overdose.
109109 6 (9) Thirty-three states have Naloxone Standing Orders
110110 7 that authorize eligible entities to have open access to
111111 8 the 8-milligram naloxone nasal spray. Those states are:
112112 9 Ohio, Kentucky, Iowa, Pennsylvania, Massachusetts, New
113113 10 Jersey, Virginia, Alabama, Florida, Tennessee, Colorado,
114114 11 Alaska, New Hampshire, Illinois, Arizona, Kansas,
115115 12 California, Texas, Georgia, South Carolina, North
116116 13 Carolina, West Virginia, Michigan, Connecticut, Oklahoma,
117117 14 Minnesota, Maine, Louisiana, Nevada, Idaho, Oregon,
118118 15 Nebraska, and Vermont.
119119 16 (10) Thirteen state government agencies have purchased
120120 17 the 8-milligram naloxone nasal spray: Alabama, Alaska,
121121 18 Colorado, Florida, Idaho, Iowa, Kentucky, New Hampshire,
122122 19 Ohio, Pennsylvania, Tennessee, Wisconsin, and West
123123 20 Virginia.
124124 21 (11) In November 2021, the U.S. Department of Veterans
125125 22 Affairs added the 8-milligram naloxone nasal spray to the
126126 23 VA National Formulary.
127127 24 (12) 70% of Americans with private health insurance
128128 25 can access the 8-milligram naloxone nasal spray.
129129 26 (13) 90% of Americans with Medicaid, including
130130
131131
132132
133133
134134
135135 HB2309 - 3 - LRB103 25361 KTG 51706 b
136136
137137
138138 HB2309- 4 -LRB103 25361 KTG 51706 b HB2309 - 4 - LRB103 25361 KTG 51706 b
139139 HB2309 - 4 - LRB103 25361 KTG 51706 b
140140 1 Medicaid recipients residing in Illinois, can access the
141141 2 8-milligram naloxone nasal spray.
142142 3 (14) The current cost of the 4-milligram naloxone
143143 4 nasal spray is $5.93 per milligram. In contrast, the
144144 5 8-milligram naloxone nasal spray costs 36.7% less at $3.75
145145 6 per milligram.
146146 7 (b) The Department of Human Services shall implement a
147147 8 2-year pilot program to provide FDA-approved 8-milligram
148148 9 naloxone nasal spray kits to licensed community substance use
149149 10 providers and public health departments in Cook County, DuPage
150150 11 County, Winnebago County, Sangamon County, and St. Clair
151151 12 County.
152152 13 The Department of Human Services shall implement a data
153153 14 collection program to determine the number of 8-milligram
154154 15 naloxone nasal spray kits administered by emergency medical
155155 16 service providers and bystanders per overdose incident during
156156 17 the 2-year term of the pilot program. The data collected must
157157 18 also include the number of individuals who survived an opioid
158158 19 overdose after receiving the 8-milligram naloxone nasal spray
159159 20 and the number of individuals who died of an opioid overdose
160160 21 after receiving the 8-milligram naloxone nasal spray.
161161 22 The Department of Human Services shall prepare a report on
162162 23 the results of the 2-year pilot program and submit the report
163163 24 to the General Assembly by July 1, 2026.
164164 25 Section 99. Effective date. This Act takes effect January
165165 26 1, 2024.
166166
167167
168168
169169
170170
171171 HB2309 - 4 - LRB103 25361 KTG 51706 b